Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, and Massey Cancer Center, Virginia Commonwealth University, PO Box 98053, 410 N. 12th Street, Richmond, VA, 23298, USA.
Department of Pharmacotherapy & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, PO Box 980533, 410 N. 12th Street, Richmond, VA, 23298, USA.
Support Care Cancer. 2023 Jul 8;31(8):450. doi: 10.1007/s00520-023-07927-9.
To assess oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients undergoing chemotherapy.
In this cross-sectional study, a questionnaire collected oncologists' perceptions about professionals responsible for managing hyperglycemia during chemotherapy; comfort (score range 12-120); and knowledge (score range 0-16). Descriptive statistics were calculated including Student t-tests and one-way ANOVA for mean score differences. Multivariable linear regression identified predictors of comfort and knowledge scores.
Respondents (N = 229) were 67.7% men, 91.3% White and mean age 52.1 years. Oncologists perceived endocrinologists/diabetologists and primary care physicians as those responsible for managing hyperglycemia during chemotherapy, and most frequently referred to these clinicians. Reasons for referral included lack of time to manage hyperglycemia (62.4%), belief that patients would benefit from referral to an alternative provider clinician (54.1%), and not perceiving hyperglycemia management in their scope of practice (52.4%). The top-3 barriers to patient referral were long wait times for primary care (69.9%) and endocrinology (68.1%) visits, and patient's provider outside of the oncologist's institution (52.8%). The top-3 barriers to treating hyperglycemia were lack of knowledge about when to start insulin, how to adjust insulin, and what insulin type works best. Women (ß = 1.67, 95% CI: 0.16, 3.18) and oncologists in suburban areas (ß = 6.98, 95% CI: 2.53, 11.44) had higher comfort scores than their respective counterparts; oncologists working in practices with > 10 oncologists had lower comfort scores (ß = -2.75, 95% CI: -4.96, -0.53) than those in practices with ≤ 10. No significant predictors were identified for knowledge.
Oncologists expected endocrinology or primary care clinicians to manage hyperglycemia during chemotherapy, but long wait times were among the top barriers cited when referring patients. New models that provide prompt and coordinated care are needed.
评估肿瘤学家在化疗患者管理高血糖方面的责任、舒适度和知识水平。
在这项横断面研究中,通过问卷调查收集肿瘤学家对化疗期间负责管理高血糖的专业人员的看法、舒适度(评分范围 12-120)和知识(评分范围 0-16)。计算描述性统计数据,包括学生 t 检验和单因素方差分析均值得分差异。多变量线性回归确定舒适度和知识得分的预测因素。
受访者(N=229)中 67.7%为男性,91.3%为白人,平均年龄为 52.1 岁。肿瘤学家认为内分泌科医生/糖尿病专家和初级保健医生是化疗期间管理高血糖的责任人,并且最常将患者转介给这些临床医生。转介的原因包括没有时间管理高血糖(62.4%)、认为患者从转介给其他提供者临床医生中获益(54.1%),以及不认为高血糖管理属于其专业范畴(52.4%)。患者转介的前 3 大障碍是初级保健(69.9%)和内分泌科(68.1%)就诊的等候时间长,以及患者的提供者不在肿瘤学家的机构内(52.8%)。治疗高血糖的前 3 大障碍是缺乏何时开始使用胰岛素、如何调整胰岛素以及哪种胰岛素类型最有效的知识。女性(ß=1.67,95%CI:0.16,3.18)和在郊区工作的肿瘤学家(ß=6.98,95%CI:2.53,11.44)的舒适度评分高于各自的对照组;在有 10 名或以上肿瘤学家的诊所工作的肿瘤学家的舒适度评分较低(ß=-2.75,95%CI:-4.96,-0.53),低于在有 10 名以下肿瘤学家的诊所工作的肿瘤学家。未发现知识水平的显著预测因素。
肿瘤学家期望内分泌科或初级保健临床医生在化疗期间管理高血糖,但当转介患者时,较长的等候时间是引用的首要障碍之一。需要新的模式来提供及时和协调的护理。